Health Care [ 2/12 ] | Biotechnology [ 3/73 ]
NASDAQ | Common Stock
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases.
The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications.
Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 11, 25 | -2.60 Decreased by -1.52 K% | - |
| Apr 28, 25 | -1.92 Decreased by -858.00% | - |
| Mar 19, 25 | -5.00 Decreased by -1.98 K% | -2.82 Decreased by -77.30% |
| Nov 1, 24 | -3.39 Decreased by -1.03 K% | -3.70 Increased by +8.38% |
| Aug 5, 24 | -0.16 Increased by +60.98% | -0.31 Increased by +48.39% |
| Apr 29, 24 | -0.20 Increased by +60.78% | -0.41 Increased by +51.22% |
| Mar 8, 24 | -0.24 Increased by +56.36% | -0.31 Increased by +22.58% |
| Nov 6, 23 | -0.30 Increased by +44.44% | -0.47 Increased by +36.17% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 0.00 Decreased by N/A% | -3.44 M Increased by +35.61% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -2.53 M Increased by +53.75% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -6.74 M Decreased by -4.11% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -3.88 M Increased by +52.27% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -5.34 M Increased by +50.32% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -5.48 M Increased by +55.94% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 1.20 M Increased by +N/A% | -6.47 M Increased by +55.69% | Decreased by -538.69% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -8.14 M Increased by +41.21% | Decreased by N/A% Decreased by N/A% |